Compare Immunovant Inc. Common Stock (IMVT) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Nokia Corp — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Nokia Corp trades at $10.3 (market cap $60.13B). The key difference: Nokia Corp is far larger — about 9.1× Immunovant Inc. Common Stock's market cap, and Nokia Corp pays a 1.54% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Nokia Corp for 66 Days on average.
| IMVT | NOK | |
|---|---|---|
Market Cap | $6.62B | $60.13B |
Volume | 1,131,364 | 71,806,452 |
Sector | Health | Technology |
52-Week High | $44.96 | $16.83 |
52-Week Low | $17.03 | $5.18 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $5.72B | $58.14B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia in high-growth infrastructure segments.
The outlook is supported by strong analyst sentiment with a consensus price target of $17.50, implying significant upside. Key opportunities include expanding AI and cloud orders, while risks involve competitive pressures and execution challenges in integrating new technologies. Cash flow volatility and a high P/E ratio of 78.9 warrant caution, but institutional buy ratings suggest confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
